Pediatrics

Validation & Orientation: Understanding Cystinosis

At a Glance

Cystinosis is a rare genetic condition where cystine builds up and forms crystals in cells, potentially damaging organs like the kidneys and eyes. Early diagnosis and consistent treatment with cysteamine can clear these crystals, allowing children to live long, fulfilling lives into adulthood.

Receiving a diagnosis of cystinosis can feel overwhelming and surreal. It is a rare journey that only about 1 in every 100,000 to 200,000 families will ever walk ^[1]. While the news is life-changing, it is important to know that you are not alone, and modern medicine has fundamentally shifted what this diagnosis means for your child’s future. Early diagnosis and consistent treatment are the most powerful tools you have to protect your child’s health and provide them with a full, active life ^[2]^[3].

What is Cystinosis?

Cystinosis is a genetic condition that affects how the body manages a specific amino acid (a building block of protein) called cystine. Normally, a protein called cystinosin acts like a “door” that lets cystine out of the cell’s recycling centers, known as lysosomes ^[4]^[5].

In children with cystinosis, the CTNS gene provides incorrect instructions, meaning these “doors” do not work properly ^[4]. As a result:

Cystine becomes trapped inside the cells ^[6].
Over time, this trapped cystine builds up and forms crystals ^[7].
These crystals can accumulate in nearly every organ, including the kidneys, eyes, liver, and muscles, potentially causing damage if left untreated ^[8]^[9].

Understanding Genetics: Autosomal Recessive

Cystinosis is an autosomal recessive condition ^[1]. This means that a child must inherit two mutated copies of the CTNS gene (one from each parent) to have the condition. The parents are usually healthy “carriers” and show no symptoms. For every future pregnancy between two carrier parents, there is a 25% chance the child will have cystinosis ^[1]^[4].

Three Ways Cystinosis Appears

While cystinosis is caused by the same genetic root, it can appear at different times and with different levels of intensity. Doctors typically categorize it into three forms:

Infantile Nephropathic Cystinosis: This is the most common and most severe form ^[10]. It typically appears in infancy or early childhood. The first signs often involve the kidneys’ inability to reabsorb nutrients (called Fanconi syndrome), which can lead to excessive thirst, frequent urination, and slow growth ^[11]^[12].
Juvenile (Late-Onset) Cystinosis: This form appears later in childhood or even during the teenage years ^[1]. The symptoms are usually milder than the infantile form, but kidney function is still the primary concern ^[13].
Ocular (Non-Nephropathic) Cystinosis: This is sometimes called the “adult” or “benign” form because it primarily affects the eyes rather than the kidneys ^[1]. While it causes light sensitivity due to crystals in the cornea, it does not typically lead to kidney failure ^[9].

Stabilizing Facts for Families

The initial shock of diagnosis is often the hardest part of the journey. Here are the core facts that can help you find your footing:

Treatment Works: Systemic treatment with cysteamine is the “gold standard” of care ^[3]. This medication helps move the trapped cystine out of the cells, which can significantly delay or even prevent many complications ^[14]^[15].
Prognosis has Changed: Before the development of modern treatments, the outlook for children with cystinosis was very different. Today, because of early detection and effective medications, children are living well into adulthood, attending college, and starting families of their own ^[16]^[17].
A Manageable Routine: While the medication schedule can be demanding, many families find that it becomes a manageable part of their daily rhythm. New delayed-release formulations may allow for dosing only twice a day, making it easier to maintain a normal lifestyle ^[18]^[19].
You are the Expert: As a parent, you will become the most important member of your child’s care team. By working closely with specialists like pediatric nephrologists (kidney doctors) and ophthalmologists (eye doctors), you can ensure your child receives the comprehensive care they need ^[20]^[8].

Common questions in this guide

What causes cystinosis?

Cystinosis is an autosomal recessive condition caused by mutations in the CTNS gene. This mutation prevents the body from properly moving the amino acid cystine out of cells, causing it to build up and form damaging crystals.

What are the different types of cystinosis?

There are three main types: infantile nephropathic, which is the most severe and affects the kidneys early on; juvenile, which appears later with milder kidney issues; and ocular, which primarily affects the eyes and causes light sensitivity.

How is cystinosis treated?

The standard of care for cystinosis is a systemic medication called cysteamine. This medication helps remove trapped cystine from the cells, which can significantly delay or prevent organ damage when taken consistently.

What is the life expectancy for someone with cystinosis?

With early diagnosis and strict adherence to modern treatments like cysteamine, the prognosis for children with cystinosis has greatly improved. Many patients now live well into adulthood, attend college, and have families of their own.

Curated prompts to bring to your next appointment.

1.Based on my child's current symptoms, which of the three types of cystinosis do they have?
2.What was my child's leukocyte cystine level at diagnosis, and what is our target goal for this level?
3.How soon can we start cysteamine therapy, and what is the plan for monitoring side effects?
4.Can you refer us to a pediatric ophthalmologist who is experienced in performing slit-lamp exams for cystinosis?
5.Does our care team include a nutritionist and a social worker to help with growth support and medication scheduling?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (20)

1
AJKD Atlas of Renal Pathology: Cystinosis.
Lusco MA, Najafian B, Alpers CE, Fogo AB
American journal of kidney diseases : the official journal of the National Kidney Foundation 2017; (70(6)):e23-e24 doi:10.1053/j.ajkd.2017.10.002.
PMID: 29169518
2
Extrarenal complications of cystinosis.
Topaloglu R
Pediatric nephrology (Berlin, Germany) 2024; (39(8)):2283-2292 doi:10.1007/s00467-023-06225-0.
PMID: 38127152
3
An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
Emma F, Hoff WV, Hohenfellner K, et al.
Kidney international 2021; (100(5)):1112-1123 doi:10.1016/j.kint.2021.06.019.
PMID: 34237326
4
CTNS mRNA molecular analysis revealed a novel mutation in a child with infantile nephropathic cystinosis: a case report.
Papizh S, Serzhanova V, Filatova A, et al.
BMC nephrology 2019; (20(1)):400 doi:10.1186/s12882-019-1589-2.
PMID: 31672123
5
Cystinosis: a review.
Elmonem MA, Veys KR, Soliman NA, et al.
Orphanet journal of rare diseases 2016; (11()):47 doi:10.1186/s13023-016-0426-y.
PMID: 27102039
6
Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction.
Elmonem MA, Khalil R, Khodaparast L, et al.
Scientific reports 2017; (7()):42583 doi:10.1038/srep42583.
PMID: 28198397
7
Nephropathic cystinosis: an update on genetic conditioning.
Topaloglu R
Pediatric nephrology (Berlin, Germany) 2021; (36(6)):1347-1352 doi:10.1007/s00467-020-04638-9.
PMID: 32564281
8
Clinical myopathy in patients with nephropathic cystinosis.
Sadjadi R, Sullivan S, Grant N, et al.
Muscle & nerve 2020; (61(1)):74-80 doi:10.1002/mus.26726.
PMID: 31588568
9
Diagnosis of Nephropathic Cystinosis in a Child During Routine Eye Exam.
Ecel M, Sarı A, Delibaş A
Turkish journal of ophthalmology 2017; (47(5)):292-295 doi:10.4274/tjo.69922.
PMID: 29109899
10
Neuromuscular conditions and the impact of cystine-depleting therapy in infantile nephropathic cystinosis: A cross-sectional analysis of 55 patients.
Vill K, Müller-Felber W, Landfarth T, et al.
Journal of inherited metabolic disease 2022; (45(2)):183-191 doi:10.1002/jimd.12464.
PMID: 34888877
11
Infantile nephropathic cystinosis with incomplete fanconi syndrome, hypothyroidism, hydro-uretero-nephrosis, and megacystis.
More V, Shanbag P
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2016; (27(3)):598-601 doi:10.4103/1319-2442.182438.
PMID: 27215258
12
Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities.
Kluck R, Müller S, Jagodzinski C, et al.
Journal of inherited metabolic disease 2022; (45(2)):192-202 doi:10.1002/jimd.12473.
PMID: 34989402
13
Nephropathic cystinosis presenting with uveitis: Report of a "Can't See, Can't Pee" situation.
Matthai SM, Jacob S, Bindra MS, et al.
Indian journal of pathology & microbiology 2019; (62(3)):457-460 doi:10.4103/IJPM.IJPM_623_18.
PMID: 31361240
14
Ocular Complications of Infantile Nephropathic Cystinosis.
Bishop R
The Journal of pediatrics 2017; (183S()):S19-S21 doi:10.1016/j.jpeds.2016.12.055.
PMID: 28343471
15
Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
Nießl C, Boulesteix AL, Oh J, et al.
Molecular genetics and metabolism 2022; (136(4)):268-273 doi:10.1016/j.ymgme.2022.06.010.
PMID: 35835062
16
An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.
Medaer L, Mora R, Zhou Z, et al.
Journal of cachexia, sarcopenia and muscle 2025; (16(6)):e70116 doi:10.1002/jcsm.70116.
PMID: 41208577
17
Gastrointestinal Manifestations of Adult Cystinosis in Iran: A Descriptive Study.
Nakhaie S, Sharif AS, Hosseini Shamsabadi R, et al.
Medical journal of the Islamic Republic of Iran 2022; (36()):15 doi:10.47176/mjiri.36.15.
PMID: 35999937
18
Local Guidance on the Management of Nephropathic Cystinosis in the Gulf Cooperation Council (GCC) Region.
Aleid H, AlShareef T, Kaddourah A, et al.
Children (Basel, Switzerland) 2025; (12(8)) doi:10.3390/children12080992.
PMID: 40868444
19
Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
Vaisbich MH, Caires Ferreira J, Price H, et al.
JIMD reports 2022; (63(1)):66-79 doi:10.1002/jmd2.12260.
PMID: 35028272
20
Pediatric cystinosis: Corneal cystine deposits and papilledema in a 4-year-old: A case report.
Choudhary DS, Shaheen J, Kala R, et al.
Medicine international 2025; (5(4)):43 doi:10.3892/mi.2025.242.
PMID: 40421228

This page provides educational information about cystinosis and its treatment. Always consult your pediatric nephrologist or care team for medical advice tailored to your child's specific diagnosis.

Get notified when new evidence is published on Cystinosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents